Cost-effectiveness of on-site antenatal screening to prevent congenital syphilis in rural eastern cape province, republic of south Africa

被引:36
作者
Blandford, John M.
Gift, Thomas L.
Vasaikar, Sandeep
Mwesigwa-Kayongo, Dan
Dlali, Pumla
Bronzan, Rachel N.
机构
[1] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA
[2] UNITRA, Umtata, Eastern Cape Pr, South Africa
关键词
SEXUALLY-TRANSMITTED-DISEASES; MATERNAL SYPHILIS; PREGNANT-WOMEN; INTERVENTION; INFECTIONS; GONORRHEA; TANZANIA;
D O I
10.1097/01.olq.0000258314.20752.5f
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: On-site screening and same-day treatment of maternal syphilis in underresourced settings can avert greater numbers of congenital syphilis cases, but health outcomes and associated costs must be evaluated jointly. Methods: We used decision analysis to estimate the incremental cost-effectiveness of two on-site antenatal syphilis screening strategies to avert congenital infections-qualitative RPR (on-site RPR) and treponemal immunochromatographic strip assay (on-site ICS)-compared to the current practice (off-site RPR/TPHA). Findings: With antenatal active syphilis prevalence of 6.3%, the incremental cost-effectiveness of on-site ICS in averting congenital infections was estimated to be USD104, averting 82% of cases expected in absence of a program. The incremental cost-effectiveness of off-site RPR/TPHA was USD82 but would avert only 55% of congenital syphilis eases. On-site RPR was dominated by the other screening strategies. Conclusions: In settings of high maternal syphilis prevalence, onsite antenatal screening with ICS is a cost-effective approach to reduce the incidence of congenital syphilis.
引用
收藏
页码:S61 / S66
页数:6
相关论文
共 17 条
  • [1] Efficacy of treatment for syphilis in pregnancy
    Alexander, JM
    Sheffield, JS
    Sanchez, PJ
    Mayfield, J
    Wendel, GD
    [J]. OBSTETRICS AND GYNECOLOGY, 1999, 93 (01) : 5 - 8
  • [2] BRONZAN R, IN PRESS ONSITE RAPI
  • [3] HIRA SK, 1990, GENITOURIN MED, V66, P159
  • [4] Ingraham NR., 1951, Acta Dermato Venereol, V31, P60
  • [5] KARUHIJE P, 2003, PILOT STUDY FEASIBIL
  • [6] MCDERMOTT J, 1993, B WORLD HEALTH ORGAN, V71, P773
  • [7] PhamKanter GBT, 1996, GENITOURIN MED, V72, P160
  • [8] Radolf JD., 1999, SEX TRANSM DIS, V3rd, P1165
  • [9] SCHULZ KF, 1987, GENITOURIN MED, V63, P320
  • [10] SCHULZ KF, 1992, REPROD BIOL, P145